Categories
Archives
- 2026
- 2025
- 2024
- 2023
- 2022
- 2021
Oct
29
UCB opens applications for 2026 UCB Myasthenia Gravis Scholarship™
Oct
27
Generalized myasthenia gravis management with shared decision-making
May
30
Recognizing Myasthenia Gravis Month – The Importance of Addressing Unmet Patient Needs
Oct
15
Powering the dreams of people impacted by myasthenia gravis (MG)
Oct
11
UCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session
Apr
12
UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting
Jan
03
ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-Acetylcholine Receptor (AChR) Antibody Positive
Nov
01
UCB presents latest data from generalized myasthenia gravis portfolio at 2023 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session
Jul
21
UCB announces U.S. availability of RYSTIGGO® (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive
